Seed Co. saw its top-line revenue grow to ¥25.52 billion, a modest increase from the ¥25.19 billion recorded in the previous year. Operating profit mirrored this steady growth, reaching ¥1.29 billion compared to ¥1.27 billion. These figures, reported under Japanese accounting standards, suggest the company maintained stable operations despite fluctuating costs in the medical manufacturing sector.

Margin Expansion and Shareholder Returns

The company’s pretax profit showed stronger momentum, climbing to ¥1.31 billion from ¥1.20 billion in the prior period. This boost in profitability directly impacted shareholder returns, with earnings per share rising to ¥29.93, up from ¥27.26. According to the financial statement, the growth reflects a combination of sustained market demand and disciplined cost management.

The nine-month results highlight several key financial milestones for the group:

• Net profit growth of approximately 9.7% year-on-year.
• A total revenue increase of ¥330 million compared to the 2024 fiscal period.
• Significant improvement in pretax income, which outpaced operating profit growth.

Seed Co. continues to focus on its core vision care business within the Japanese market. While the report did not detail specific segment performance, the overall trajectory remains positive as the company moves toward the end of its fiscal year on March 31, 2025.